Prestige BioPharma Limited
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in im… Read more
Prestige BioPharma Limited (950210) - Net Assets
Latest net assets as of September 2025: ₩499.31 Billion KRW
Based on the latest financial reports, Prestige BioPharma Limited (950210) has net assets worth ₩499.31 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩714.76 Billion) and total liabilities (₩215.44 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩499.31 Billion |
| % of Total Assets | 69.86% |
| Annual Growth Rate | 51.2% |
| 5-Year Change | -12.04% |
| 10-Year Change | N/A |
| Growth Volatility | 112.25 |
Prestige BioPharma Limited - Net Assets Trend (2018–2025)
This chart illustrates how Prestige BioPharma Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Prestige BioPharma Limited (2018–2025)
The table below shows the annual net assets of Prestige BioPharma Limited from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | ₩505.76 Billion | -1.89% |
| 2024-06-30 | ₩515.50 Billion | -5.63% |
| 2023-06-30 | ₩546.23 Billion | +27.05% |
| 2022-06-30 | ₩429.94 Billion | -25.22% |
| 2021-06-30 | ₩574.96 Billion | +317.24% |
| 2020-06-30 | ₩137.80 Billion | +136.82% |
| 2019-06-30 | ₩58.19 Billion | +107.89% |
| 2018-06-30 | ₩27.99 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prestige BioPharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26001702498600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩709.52 Billion | 173.50% |
| Other Comprehensive Income | ₩-4.19 Billion | -1.02% |
| Total Equity | ₩408.95 Billion | 100.00% |
Prestige BioPharma Limited Competitors by Market Cap
The table below lists competitors of Prestige BioPharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
I&C Technology Co. Ltd
KQ:052860
|
$23.89 Million |
|
West Vault Mining Inc
OTCQX:WVMDF
|
$23.89 Million |
|
Spyrosoft S.A.
WAR:SPR
|
$23.90 Million |
|
HMA AGRO INDUSTRIES ORD (BSE)
NSE:HMAAGRO
|
$23.90 Million |
|
VRX Silica Ltd
AU:VRX
|
$23.88 Million |
|
Ausquest Ltd
AU:AQD
|
$23.88 Million |
|
Red Pine Exploration Inc
OTCQB:RDEXF
|
$23.87 Million |
|
BAHADIR KIMYA
IS:BAHKM
|
$23.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prestige BioPharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 439,087,428,000 to 408,949,517,000, a change of -30,137,911,000 (-6.9%).
- Net income of 22,272,534,000 contributed positively to equity growth.
- New share issuances of 1,117,295,000 increased equity.
- Other comprehensive income increased equity by 93,262,000.
- Other factors decreased equity by 53,621,002,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩22.27 Billion | +5.45% |
| Share Issuances | ₩1.12 Billion | +0.27% |
| Other Comprehensive Income | ₩93.26 Million | +0.02% |
| Other Changes | ₩-53.62 Billion | -13.11% |
| Total Change | ₩- | -6.86% |
Book Value vs Market Value Analysis
This analysis compares Prestige BioPharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 104.56x to 1.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-06-30 | ₩93.15 | ₩9740.00 | x |
| 2019-06-30 | ₩193.65 | ₩9740.00 | x |
| 2020-06-30 | ₩458.60 | ₩9740.00 | x |
| 2021-06-30 | ₩10579.44 | ₩9740.00 | x |
| 2022-06-30 | ₩7154.15 | ₩9740.00 | x |
| 2023-06-30 | ₩7496.51 | ₩9740.00 | x |
| 2024-06-30 | ₩7306.43 | ₩9740.00 | x |
| 2025-06-30 | ₩6804.94 | ₩9740.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prestige BioPharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.45%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 155.64%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.81x
- Recent ROE (5.45%) is above the historical average (-8.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -7.96% | 0.00% | 0.00x | 1.47x | ₩-5.03 Billion |
| 2019 | -2.49% | -69.29% | 0.02x | 1.77x | ₩-7.27 Billion |
| 2020 | -10.88% | 0.00% | 0.00x | 1.16x | ₩-28.78 Billion |
| 2021 | -1.29% | 0.00% | 0.00x | 1.05x | ₩-64.89 Billion |
| 2022 | -49.18% | 0.00% | 0.00x | 1.16x | ₩-254.44 Billion |
| 2023 | 3.90% | 10855.89% | 0.00x | 1.65x | ₩-27.48 Billion |
| 2024 | -7.50% | -4777.60% | 0.00x | 1.62x | ₩-76.83 Billion |
| 2025 | 5.45% | 155.64% | 0.02x | 1.81x | ₩-18.62 Billion |
Industry Comparison
This section compares Prestige BioPharma Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prestige BioPharma Limited (950210) | ₩499.31 Billion | -7.96% | 0.43x | $23.88 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |